Researchers have shown that aberrant expression of CDKN2A is linked to the onset of malignant tumors such lung cancer, breast cancer, bone tumors, and skin cancer when homozygous deletion of CDKN2A is present [10, 20, 21]. Here, CDKN2A is linked to bone neoplasm.